

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1617
Examiner Name	Jennifer Kim
Attorney Docket Number	CRD5073USNP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		3,929,992		Sehgal et al.	12-30-1975	
		3,959,078		Guire et al.	05-25-1976	
		4,350,160		Kolesov	09-21-1982	
		4,366,819		Kaster	01-04-1983	
		4,368,736		Kaster	01-18-1983	
		4,624,257		Berggren et al.	11-25-1986	
		4,722,906		Guire et al.	02-02-1988	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				
		WO	04/011000	A	Wyeth	02-05-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		AJROLDI et al., "Fluoroelastomers-dependence of relaxation phenomena on compositions", <i>Polymer</i> 30, 2180 (1989)	
		ARCELLA, V. et al., "Fluorocarbon Elastomers", <i>Modern Fluoropolymers</i> , (J. Shires ed.), John Wiley & Sons, New York, pp. 77-87 (1997)	
		BERK, B.C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After...", <i>J. Am. College Cardiology</i> 17: 111B-117B (1991)	
		CARRERA et al., "Potent Toxicity of 2-Chlorodeoxyadenosine toward Human Monocytes in Vitro and In Vivo" <i>J. Clin. Invest.</i> 86: 1480-1488 (1990)	
		CARSON, D.A. et al., "Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes", <i>Blood</i> 62: 737-743 (1983)	
		CHANG, M. W. et al., "Adenovirus-mediated Over-expression..." <i>J. Clin. Invest.</i> 96: 2260-2268 (1995)	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ¹⁶ if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1617
Examiner Name	Jennifer Kim
Attorney Docket Number	CRD5073USNP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		4,733,665		PalmaZ	03-29-1988	
		4,739,762		PalmaZ	04-26-1988	
		4,776,337		PalmaZ	10-11-1988	
		4,917,090		Berggren et al.	04-17-1990	
		4,917,091		Berggren et al.	04-17-1990	
		5,229,172		Cahalan et al.	07-20-1993	
		5,234,447		Kaster et al.	08-10-1993	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CLOWES, A. W. et al. "Suppression by heparin of smooth..." <u>Nature</u> 265: 625-626 (1977)	
		CLOWES, A.W. et al. "Kinetics of Cellular Proliferation..." <u>Lab. Invest.</u> 52: 611-616 (1985)	
		CLOWES, A.W. et al., "Kinetics of Cellular Proliferation..." <u>Circ. Res.</u> 58: 839-845 (1986)	
		COLBURN, M.D. et al., "Done responsive suppression of..." <u>J. Vasc. Surg.</u> 15: 510-518 (1992)	
		CURRIER, J.W. et al., <u>Circ.</u> 80: 11-66 (1989)	
		DEROANNE, C.F. et al., "Histone deacetylases inhibitors...", <u>Oncogene</u> 21 (3): 427-436 (2002)	
		FARB, A. et al., "Vascular Smooth Muscle Cell Cytotoxicity...", <u>Circ. Res.</u> 80: 542-550 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1617
Examiner Name	Jennifer Kim
Attorney Docket Number	CRD5073USNP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		5,308,641		Cahalan et al.	05-03-1994	
		5,350,800		Verhoeven	09-27-1994	
		5,415,938		Cahalan et al.	05-16-1995	
		5,837,313		Ding et al.	11-17-1998	
		6,099,562		Ding et al.	08-08-2000	
		6,120,536		Ding et al.	09-19-2000	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FERNS, G.A.A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation after Angioplasty...", <u>Science</u> 253: 1129-1132 (1991)	
		FUKUYAMA, J. et al., "Tranilast suppresses the vascular intimal hyperplasia after balloon injury..." <u>Eur. J. Pharmacol.</u> 318: 327-332 (1996)	
		GUYTON, J.R. et al., "Inhibition of Rat Arterial Smooth Muscle..." <u>Circ. Res.</u> 46: 625-634 (1980)	
		HANSON, S.R. et al, "Interruption of acute platelet-dependent thrombosis by the synthetic..." <u>Proc. Natl. Acad. Sci. USA</u> 85: 3184-3188 (1988)	
		HANSSON, G.K. et al., "Interferon- γ Inhibits Arterial Stenosis ..." <u>Circ.</u> 84: 1266-1272 (1991)	
		JONASSON, L. et al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury" <u>Proc. Natl. Acad. Sci.</u> 85: 2303 (1988)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1617
Examiner Name	Jennifer Kim
Attorney Docket Number	CRD5073USNP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Date Considered
		LIU, M.W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit" <i>Circ.</i> 81: 1089-1093 (1990)	
		LUNDERGAN, C.F. et al., "Peptide Inhibition of Myointimal Proliferation by Angiopeptin...." <i>Am. J. Cardiol.</i> 17 (Suppl. B): 132B-136B (1991)	
		MAJESKY, M.W. et al., "Heparin Regulates Smooth Muscle S Phase Entry In the Injured Rat Carotid Artery" <i>Circ. Res.</i> 61: 296-300 (1987)	
		MARX, S.O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation In Vascular Smooth Muscle Cells" <i>Circ. Res.</i> 76: 412-417 (1995)	
		NEMECEK, G.M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor <i>in Vitro</i> and Neointimal Proliferation <i>in Vivo</i> " <i>J. Pharmacol. Exp. Thera.</i> 248: 1167-1174 (1989).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. ¹⁶ if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Confirmation Number	7706
Application Number	10/813,965
Filing Date	March 31, 2004
First Named Inventor	Robert Falotico
Group Art Unit	1617
Examiner Name	Jennifer Kim
Attorney Docket Number	CRD5073USNP

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	KindCode ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		OKADA, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation After Endothelial Injury without Systemic Anticoagulation" <u>Neurosurgery</u> 25: 892-898 (1989)	
		POWELL, J. S. et al., "Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury" <u>Science</u> , 245: 186-188 (1989)	
		SIMONS, M. et al., "Antisense <i>c-myb</i> oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> " <u>Nature</u> 359: 67-70 (1992)	
		SNOW, A.D. et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding..." <u>Am. J. Pathol.</u> 137: 313-330 (1990)	
		SOLLOT, S.J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty in the Rat" <u>J. Clin. Invest.</u> 95: 1869-1876 (1995)	
		WEINBERGER, J. et al., "Intracoronary Irradiation: Dose response For The Prevention of Restenosis in Swine" <u>Int. J. Rad. Onc. Biol. Phys.</u> 36: 767-775 (1996)	
		WOO, S.H. et al., "Structurally Simple Trichostatin A-Like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors" <u>J. Med Chem.</u> 45: 2877-2885 (2002)	

Examiner Signature	Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of U.S. Patent Documents at www.uspto.gov. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450